Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pierre Fabre
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.
Data from the Extracorporeal Life Support Organization registry shows experienced centers should consider using extracorporeal membrane oxygenation to treat COVID-19-related respiratory failure.
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
- Pharmacy Services, PBMs
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Pierre Fabre Medicament S.A.